Dental Intelligence vs Incyte
Side-by-side comparison of AI visibility scores, market position, and capabilities
Practice analytics and patient engagement platform for dental offices helping DSOs and independents grow production. American Fork UT; founded 2016; connects to 100+ dental PMS systems; turns existing practice data into actionable insights for improving collections, reappointment rates, and treatment acceptance.
About
Dental Intelligence is an American Fork, Utah-based dental practice analytics and patient engagement platform that helps dental offices, group practices, and dental support organizations (DSOs) analyze production data, identify growth opportunities, and improve patient engagement and retention. Founded in 2016, the company built its platform around a core insight: most dental practices generate enormous amounts of operational data in their practice management software but lack the tools to turn that data into actionable insights. Dental Intelligence connects to over 100 dental practice management systems—including Dentrix, Eaglesoft, OpenDental, and Carestream—and automatically analyzes key performance indicators including production per provider, case acceptance rates, recall effectiveness, hygiene reappointment rates, and collections performance.\n\nThe platform's patient engagement tools allow dental practices to automate appointment reminders, recall outreach, and reactivation campaigns for patients who are overdue for cleanings or who have unscheduled treatment plans. These engagement automations reduce the manual administrative burden on front desk staff while improving patient show rates and reducing last-minute cancellations that disrupt production schedules. Dental Intelligence's analytics layer surfaces the specific operational levers most likely to drive revenue growth for each practice—whether that is improving treatment plan acceptance, filling hygiene chairs more efficiently, or reducing same-day cancellations.\n\nDental Intelligence has found particular traction with multi-location DSO customers that need consistent performance analytics and benchmarking across dozens or hundreds of dental practices. The platform's DSO-tier dashboards allow regional managers and corporate leadership to compare location performance, identify underperforming practices, and replicate the operational practices of top performers. The company competes with Weave, Solutionreach, and Carestream Dental in the dental technology market, differentiating on the depth of its practice analytics and its broad integration with existing dental practice management systems.
Wilmington DE oncology/inflammation biopharma (NASDAQ: INCY) ~$3.9B FY2024 revenue; Jakafi $2.7B myelofibrosis franchise, Opzelura topical JAK inhibitor, Novartis Jakavi royalties competing with BMS and Pfizer.
About
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company — publicly traded on the NASDAQ (NASDAQ: INCY) as an S&P 500 Health Care component — focused on oncology and inflammation, best known for Jakafi (ruxolitinib), the first FDA-approved therapy for myelofibrosis and polycythemia vera — rare blood cancers driven by JAK kinase pathway mutations — and the topical ruxolitinib cream Opzelura (for atopic dermatitis and vitiligo). In fiscal year 2024, Incyte reported revenues of approximately $3.9 billion, with Jakafi net product revenues of approximately $2.7 billion (the primary revenue driver) and collaboration revenues from Novartis (which pays Incyte royalties on Jakavi — the ex-US brand name for ruxolitinib — representing a significant royalty income stream from international myelofibrosis and polycythemia vera markets). CEO Hervé Hoppenot's strategy of building a diversified hematology-oncology pipeline beyond ruxolitinib has progressed through the development of axatilimab (anti-CSF-1R monoclonal antibody for chronic graft-versus-host disease — FDA-approved 2024 as Niktimvo) and povorcitinib (JAK inhibitor for prurigo nodularis and hidradenitis suppurativa — phase 3 trials in dermatology). Incyte's JAK inhibitor chemistry platform (ruxolitinib — Jakafi/Opzelura/Jakavi, parsaclisib, itacitinib, tofacitinib licensed from Pfizer collaboration) provides a productive medicinal chemistry foundation for developing next-generation kinase inhibitors with more selective pharmacology profiles.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.